resveratrol has been researched along with alpha-synuclein in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, JS; Kim, JH; Lee, JH; Paik, SR | 1 |
| Albani, D; Batelli, S; Caccia, S; Colombo, L; De Mauro, S; Forloni, G; Fracasso, C; Manzoni, C; Martelli, G; Negro, A; Polito, L; Salmona, M | 1 |
| Fan, Z; Jankovic, J; Le, W; Li, X; Pan, T; Wu, Y; Xie, W; Zhu, JX | 1 |
| Bayer, H; Danzer, KM; Eschbach, J; Fauler, M; Liss, B; Ludolph, AC; McLean, PJ; Morrison, BE; Müller, K; Otto, M; Rudolph, KL; Scheffold, A; Spada, AR; Thal, DR; von Einem, B; Weishaupt, JH; Weydt, P; Witting, A | 1 |
| Duan, YL; Li, GF; Wang, ZH; Zhang, JL; Zhang, QS; Zheng, DL | 1 |
| Cui, XX; Dong, SY; Feng, Y; Guo, YJ; Kuo, SH; Liu, T; Tan, EK; Wu, YC; Yin, M; Zhao, WJ | 1 |
| Sui, R; Xia, D; Zhang, Z | 1 |
| Ji, M; Liu, RT; Liu, SY; Wang, YJ; Wu, XL; Yu, XL; Zhang, LF | 1 |
| Chau, E; Kim, H; Kim, JR; Martinez, A; Shin, J | 1 |
| Elyasi, L; Jahanshahi, M; Jesmi, F; Rosenholm, JM | 1 |
1 review(s) available for resveratrol and alpha-synuclein
| Article | Year |
|---|---|
The Antioxidative Effects of Picein and Its Neuroprotective Potential: A Review of the Literature.
Topics: alpha-Synuclein; Animals; Antioxidants; Curcumin; Glucosides; Neurodegenerative Diseases; Neuroprotective Agents; Panax; Resveratrol; tau Proteins; Withania | 2022 |
9 other study(ies) available for resveratrol and alpha-synuclein
| Article | Year |
|---|---|
Novel method for quantitative determination of amyloid fibrils of alpha-synuclein and amyloid beta/A4 protein by using resveratrol.
Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Amyloidosis; Benzothiazoles; Humans; Protein Structure, Quaternary; Resveratrol; Spectrometry, Fluorescence; Stilbenes; Thiazoles | 2007 |
The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide.
Topics: alpha-Synuclein; Amino Acid Sequence; Amyloid beta-Peptides; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Molecular Sequence Data; Oxidative Stress; Peptide Fragments; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes | 2009 |
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease.
Topics: alpha-Synuclein; AMP-Activated Protein Kinases; Animals; Antioxidants; Autophagy; Cell Line, Transformed; Dose-Response Relationship, Drug; Doxycycline; Gene Expression Regulation; Humans; Insecticides; Microscopy, Immunoelectron; Microtubule-Associated Proteins; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rats; Resveratrol; RNA, Small Interfering; Rotenone; Signal Transduction; Sirtuin 1; Stilbenes; Time Factors | 2011 |
Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Animals; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Embryo, Mammalian; Enzyme Inhibitors; Female; Gene Expression Regulation; Glioma; Humans; Macrolides; Male; Mice; Mice, Transgenic; Middle Aged; Neurons; Parkinson Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Resveratrol; RNA Polymerase II; Stilbenes; Substantia Nigra; TATA-Box Binding Protein; Transcription Factors | 2015 |
MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson's disease mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation; Humans; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Neuroblastoma; Neuroprotective Agents; Parkinsonian Disorders; Resveratrol; RNA, Messenger; Stilbenes; Up-Regulation | 2015 |
Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; alpha-Synuclein; Animals; Autophagy; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice, Inbred C57BL; Microtubule-Associated Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Resveratrol; Sirtuin 1; Stilbenes | 2016 |
Administration of resveratrol improved Parkinson's disease-like phenotype by suppressing apoptosis of neurons via modulating the MALAT1/miR-129/SNCA signaling pathway.
Topics: alpha-Synuclein; Animals; Apoptosis; Mice; MicroRNAs; Neurons; Parkinson Disease, Secondary; Resveratrol; RNA, Long Noncoding; Signal Transduction | 2019 |
Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cognition; Disease Models, Animal; Humans; Male; Mice; Mice, Transgenic; Motor Activity; Mutation, Missense; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Resveratrol | 2018 |
Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative.
Topics: alpha-Synuclein; Humans; Molecular Structure; Protein Aggregates; Resveratrol | 2021 |